GeneOrigin Genetics Files IPO Prospectus: Integrated Solutions for Pediatric and Ophthalmic Genetic Disorders

Since the beginning of the 21st century, life sciences, represented by genetic technologies, have entered a phase of rapid development, accompanied by the commercial launch of a series of products and services. The primary applications of gene sequencing fall into two major categories: clinical applications and scientific research testing. Within the realm of clinical applications, the vast majority of genetic companies have concentrated their efforts on reproductive health and oncology genetic testing. In the field of reproductive health, compared to the relatively mature non-invasive prenatal screening (NIPS) products, there are fewer genetic companies specializing in the diagnosis of rare and hereditary diseases. VCBeat (WeChat ID: vcbeat) found in its review that domestic enterprises involved in genetic diagnosis for rare diseases still primarily focus on oncology genetic testing.

Jiyuan Gene is a comprehensive enterprise with core competencies in genetic testing and big data analysis of genomes, dedicated to research and services in technologies such as gene-assisted diagnosis of genetic diseases and personalized diagnosis and treatment., providing integrated solutions for genetic diseases.

Yao Xun, CEO of Jiyuan Genomics, told VCBeat that the company is committed to “helping patients avoid unnecessary detours.” Unlike tumor genetic testing, diagnosing complex genetic disorders often requires genetic testing for confirmation, followed by the establishment of a corresponding treatment plan based on the test results. In short, genetic diagnosis is an essential requirement for the treatment of rare and hereditary diseases.

However, meeting patient needs requires more than just providing genetic testing; it also demands a broader range of extended services. Jiyuan integrates its products into a closed-loop service system, leveraging a “three-pronged approach” to address a spectrum of patients’ medical needs. With a focus on pediatrics and ophthalmology, the company enables patients to identify the optimal treatment plan through the fastest channels in the shortest possible time.

Yao Xun explained to VCBeat: “The ‘three pillars’ are: 1. a genetic disease gene-assisted diagnostic system for hospital physicians (Jiyuan Sou), 2. an online genetic counseling platform for patients and their families (Genetic Counseling Community), and 3. an offline clinical genetic diagnostic center (Jiyuan Medical Laboratory).”

Jiyuansou is an AI-assisted diagnostic system for genetic disorders, designed specifically for clinicians. It enables physicians to rapidly and accurately narrow down the differential diagnosis of genetic conditions, match clinical phenotypes with diseases in real time, and precisely select appropriate diagnostic and therapeutic pathways. The system is scheduled for deployment in the pediatric outpatient information system at the First Affiliated Hospital of Xiamen University by the end of this year, benefiting over 600,000 individuals annually.

Genetic Counseling Community is an online consultation platform launched by Jiyuan Gene in July 2018, serving all patients with genetic disorders and their families. The launch of the Genetic Counseling Community not only addresses the severe lack of knowledge about genetic diseases among patients and their families but also provides clinicians with a clear patient profile, thereby improving the efficiency of diagnosis and treatment for genetic disorders.

Jiyuan Medical Laboratory is a third-party medical testing laboratory established offline by Jiyuan Gene and approved by the National Health and Family Planning Commission. Its robust teams in R&D, experimental science, bioinformatics, and genetic analysis provide precise diagnoses for every patient.

Yao Xun emphasized that these three major products are not isolated; rather, they comprehensively cover the entire patient journey, including pre-diagnosis, during-diagnosis, and post-diagnosis phases. Jiyuan aims to provide patients with holistic solutions and integrated services. Unlike companies that focus primarily on core technologies, Jiyuan positions itself as a product-based service company, delivering more human-centric, comprehensive, and integrated services to genuinely address patient needs. This approach also facilitates data accumulation, enabling the company to possess the most complete single-disease dataset in the future.

Delivering high-quality services built upon competitive products. The core competency of the GeneOrigin team lies in applying advanced technologies to various clinical diagnosis and treatment scenarios from the perspectives of both physicians and patients. Over 90% of GeneOrigin’s core team members hold master’s or doctoral degrees, including MDs and MScs with frontline clinical experience, as well as seasoned managers with extensive marketing expertise and a track record of serial entrepreneurship.

The clinical application of the genomics industry also follows the sector’s developmental trajectory. In the upstream segment of the gene sequencing industry, the market has matured with Illumina holding a dominant position. The midstream primarily involves sequencing services and the processing and interpretation of sequencing data, where future competition will hinge on data analytics capabilities. The downstream segment comprises end-user applications of sequencing services, mainly serving clinical applications and life sciences research. As sequencing technology matures and costs decline, enabling the integration of genetic testing into clinical practice, end-user applications that address the effective needs of more patients are poised for explosive growth.

Yao Xun also stated, “The entire gene sequencing market is currently at the ‘trough of disillusionment’ on the Hype Cycle, poised to reach a breakthrough point for exponential growth. It is also in the ‘early adopters’ stage of the Innovation Diffusion Curve, on the verge of entering the ‘early majority’ phase. Whether it achieves a growth breakthrough or gains broader adoption among the general public at the medical-grade level, the trend toward clinical application endpoints is unstoppable.”

Regarding future plans, Yao Xun told VCBeat, “Jiyuan Gene will continue to focus on the fields of pediatrics and ophthalmology, and even further narrow its focus to specific diseases. In terms of market layout, after more than two years of market refinement, Jiyuan Gene has acquired the strength and conditions necessary for a nationwide presence across China. At present, our primary markets are concentrated in East and South China. Therefore, we will position ourselves as a life and health industry company centered on genetic technology. We anticipate numerous application scenarios, potentially serving as a connector across various sectors. I can envision 5–10 subsequent market opportunities. However, for now, we remain focused on the niche segment of ‘genetic diagnosis of hereditary diseases.’”

Currently, the company is seeking financing.